This approach holds substantial clinical promise for improving the tumor immune landscape in NSCLC and other solid tumors, while reversing both primary and acquired resistance to PD‐1/PD‐L1 therapies (Scheme1). This evidence concerns the gene CD274 and non-small cell lung carcinoma.